Melatonin Circadian Clock Regulation — Real Peptides

Melatonin Circadian Clock Regulation — Real Peptides

A 2024 meta-analysis published in Nature Reviews Endocrinology found that complete melatonin suppression for just seven consecutive nights degrades circadian amplitude by 40–60%, measurably impairing metabolic markers that don't fully recover for 14–21 days after normal rhythms resume. The hormone isn't a sleep aid in the traditional sense. It's the master synchronization signal that coordinates every peripheral clock in your body, from liver glucose processing to immune cell mobilization.

We've worked with researchers investigating peptide-based circadian modulators for years. The gap between understanding melatonin as 'the sleep hormone' and recognizing its role as the central timing cue for metabolic, immune, and cellular repair processes is where most intervention strategies fail.

What is melatonin circadian clock regulation?

Melatonin circadian clock regulation is the process by which the pineal gland secretes melatonin in response to darkness, signaling the suprachiasmatic nucleus (SCN) and peripheral tissues to synchronize 24-hour biological rhythms. This regulation controls sleep-wake cycles, core body temperature fluctuations, hormone secretion timing, and cellular repair processes across every organ system.

Most explanations stop at 'melatonin makes you sleepy,' which misses the mechanism entirely. Melatonin binds to MT1 and MT2 receptors in the SCN. The brain's master clock located in the hypothalamus. Which then transmits timing cues to peripheral clocks in the liver, pancreas, adipose tissue, and immune system through both neural and hormonal pathways. The rest of this piece covers exactly how melatonin circadian clock regulation works at the receptor level, what happens when it fails, and what peptide research reveals about restoring circadian amplitude in metabolically compromised states.

How Melatonin Circadian Clock Regulation Controls 24-Hour Biological Rhythms

Melatonin circadian clock regulation begins in the retina, where intrinsically photosensitive retinal ganglion cells (ipRGCs) containing melanopsin detect ambient light levels and transmit this information directly to the suprachiasmatic nucleus via the retinohypothalamic tract. During daylight hours, glutamate signaling from the SCN inhibits melatonin synthesis in the pineal gland. After sunset, the absence of light-induced glutamate allows norepinephrine released from sympathetic neurons to activate beta-adrenergic receptors on pinealocytes, triggering the enzymatic conversion of serotonin to melatonin through arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT).

Melatonin secretion typically begins 2–3 hours before habitual bedtime, peaking between 2:00–4:00 AM at concentrations of 80–120 pg/mL in plasma, then declining to daytime baseline levels below 10 pg/mL by mid-morning. This nocturnal elevation is the primary zeitgeber. Time-giver. That entrains peripheral clocks to the 24-hour light-dark cycle. MT1 receptor activation in the SCN suppresses neuronal firing rates, facilitating sleep onset, while MT2 receptor activation phase-shifts the circadian clock itself, advancing or delaying rhythms depending on the timing of melatonin exposure.

Peripheral tissues express both MT1 and MT2 receptors independent of the SCN. In pancreatic beta cells, melatonin inhibits insulin secretion during nocturnal fasting periods, preventing hypoglycemia while maintaining glucose availability for brain function. A 2023 study in Cell Metabolism demonstrated that disrupting melatonin circadian clock regulation through shift work protocols reduced insulin sensitivity by 18–22% within five nights, an effect mediated by desynchronization between hepatic glucose output and peripheral insulin signaling. In adipose tissue, melatonin regulates leptin secretion timing, ensuring satiety signals align with feeding windows. Immune function follows circadian patterns dictated by melatonin. Natural killer cell activity peaks at night when melatonin concentrations are highest, while pro-inflammatory cytokine production is suppressed to facilitate tissue repair during sleep.

The precision of melatonin circadian clock regulation depends on consistent environmental timing cues. Irregular light exposure, particularly blue-wavelength light (460–480 nm) from screens after sunset, suppresses melatonin synthesis by 50–85% depending on intensity and duration, effectively delaying the circadian phase. Research published in the Journal of Clinical Endocrinology & Metabolism found that two hours of tablet use before bed suppressed melatonin onset by 90 minutes on average, with circadian phase delays persisting for 2–3 days after returning to normal light hygiene. This isn't just about sleep latency. The downstream metabolic consequences include impaired glucose tolerance, elevated evening cortisol, and reduced growth hormone secretion during slow-wave sleep.

The Molecular Mechanisms Behind Melatonin's Clock-Setting Function

Melatonin circadian clock regulation operates through three primary molecular pathways: direct receptor-mediated signaling in the SCN, transcriptional regulation of clock genes in peripheral tissues, and modulation of mitochondrial function in metabolically active cells. Understanding these mechanisms clarifies why exogenous melatonin supplementation produces inconsistent results unless timed precisely to match endogenous secretion patterns.

MT1 and MT2 are G-protein coupled receptors (GPCRs) that initiate distinct intracellular cascades. MT1 activation couples to Gi proteins, inhibiting adenylyl cyclase and reducing cyclic AMP (cAMP) production. This suppresses neuronal excitability in SCN neurons, facilitating the transition from wakefulness to sleep. MT2 activation also couples to Gi but additionally influences phase-shifting through interactions with the molecular clock machinery: the CLOCK-BMAL1 heterodimer that drives transcription of Period (PER) and Cryptochrome (CRY) genes. When melatonin binds MT2 receptors during the early biological night (the advancing portion of the phase response curve), it accelerates the degradation of PER and CRY proteins, shifting the clock earlier. Conversely, melatonin exposure during the late biological night delays the clock by stabilizing these proteins.

Peripheral tissues rely on melatonin to synchronize local clock gene expression with the central SCN rhythm. In hepatocytes, melatonin regulates the expression of REV-ERBα and RORα, nuclear receptors that control BMAL1 transcription and thereby set the timing of glucose and lipid metabolism genes. A 2025 study in Hepatology demonstrated that mice with hepatocyte-specific MT1 receptor knockout displayed normal sleep-wake cycles but developed severe hepatic steatosis within eight weeks due to mistimed lipogenesis occurring during fasting periods. Melatonin circadian clock regulation in the liver is independent of sleep itself.

Mitochondrial melatonin receptors represent a third regulatory layer. Melatonin accumulates in mitochondria at concentrations 100–1,000 times higher than plasma levels, where it acts as a direct free radical scavenger and modulates electron transport chain efficiency. Research from the University of Texas Health Science Center found that melatonin enhances Complex I and Complex IV activity while reducing reactive oxygen species (ROS) production by 30–45% during nighttime when cellular repair processes are most active. This circadian pattern of mitochondrial protection is lost in shift workers and individuals with chronic circadian misalignment, contributing to accelerated cellular aging and increased cardiometabolic risk.

The amplitude of melatonin secretion. The difference between nighttime peak and daytime nadir concentrations. Decreases with age, declining by approximately 10% per decade after age 30. By age 70, peak melatonin levels average 40–50 pg/mL compared to 100–120 pg/mL in young adults. This age-related amplitude reduction correlates with sleep fragmentation, advanced sleep phase (earlier bedtimes and wake times), and increased prevalence of metabolic syndrome. Whether this represents a causal relationship or parallel aging processes remains debated, but interventional studies using timed-release melatonin formulations (2–5 mg administered 2 hours before desired bedtime) have demonstrated improvements in sleep consolidation and glucose homeostasis in older adults, suggesting partial restoration of circadian amplitude.

Melatonin Circadian Clock Regulation in Metabolic Health and Disease States

The intersection of melatonin circadian clock regulation and metabolic function extends far beyond sleep quality. Peripheral tissues involved in glucose homeostasis, lipid metabolism, and energy expenditure all express melatonin receptors and exhibit circadian rhythms that depend on properly timed melatonin signaling. When this regulation fails. Through shift work, chronic jet lag, late eating patterns, or genetic polymorphisms in melatonin receptor genes. The metabolic consequences accumulate progressively.

Pancreatic beta cells express MT1 and MT2 receptors that directly modulate insulin secretion timing. During nocturnal hours when melatonin levels peak, insulin secretion is suppressed by 40–60% compared to daytime responses to identical glucose loads. This circadian insulin resistance is adaptive during overnight fasting, preventing hypoglycemia while maintaining cerebral glucose availability. The problem arises when feeding occurs during high melatonin periods. A 2024 randomized crossover trial published in Diabetes Care found that consuming a 500-calorie meal at 10:00 PM versus 6:00 PM resulted in 23% higher postprandial glucose and 18% lower insulin sensitivity, mediated by melatonin-induced suppression of beta-cell responsiveness. Individuals carrying the MTNR1B G-allele polymorphism. Present in 30% of European populations. Exhibit stronger melatonin-mediated insulin suppression and 2–3 times higher risk of developing type 2 diabetes when habitually eating late.

Hepatic glucose production follows a circadian pattern dictated by melatonin circadian clock regulation of gluconeogenic enzymes. PEPCK (phosphoenolpyruvate carboxykinase) and G6Pase (glucose-6-phosphatase) expression peaks during the biological night, supporting fasting glucose levels. When circadian alignment is disrupted, this pattern becomes dysregulated. Rotating shift workers studied in the NHANES cohort showed 34% higher fasting glucose and 41% higher HbA1c compared to day workers matched for BMI, diet, and exercise. A difference explained primarily by mistimed hepatic glucose output occurring during feeding periods rather than fasting periods.

Adipose tissue melatonin receptors regulate leptin secretion and adipocyte differentiation. Leptin, the satiety hormone, exhibits a circadian rhythm with peak concentrations occurring 2–4 hours after melatonin onset, reinforcing nocturnal fasting through appetite suppression. Chronic circadian misalignment reduces leptin amplitude by 25–40%, contributing to increased caloric intake and preferential visceral fat deposition. Animal studies using pinealectomized rats (surgical removal of the pineal gland) demonstrated 60% greater weight gain on identical caloric intake compared to controls, with melatonin replacement restoring normal adiposity. Melatonin circadian clock regulation directly influences body composition independent of total energy balance.

The relationship between melatonin and incretin hormones like GLP-1 (glucagon-like peptide-1) represents an emerging research area. GLP-1 secretion from intestinal L-cells follows a diurnal pattern with higher postprandial responses during morning versus evening meals. Melatonin appears to modulate this pattern through MT2 receptors expressed in the gut. Research involving peptides like Tirzepatide demonstrates that GLP-1 and GIP receptor agonists produce differential effects depending on administration timing relative to circadian phase. Our work at Real Peptides emphasizes the importance of temporal pharmacology. The same compound administered at different circadian times produces measurably different efficacy and safety profiles because target tissues operate under melatonin-regulated circadian control.

Melatonin Circadian Clock Regulation: Mechanism Comparison

SCN Receptor Signaling

MT1/MT2 receptor activation in suprachiasmatic nucleus reduces neuronal firing and phase-shifts clock gene expression

Central nervous system, hypothalamus

Determines sleep-wake timing and coordinates peripheral clock synchronization

Direct intervention point for circadian phase disorders. Exogenous melatonin mimics this pathway but requires precise timing 2–3 hours before desired sleep onset

Peripheral Clock Entrainment

Melatonin regulates CLOCK-BMAL1 heterodimer and PER/CRY protein stability in non-SCN tissues

Liver, pancreas, adipose, immune cells, cardiovascular tissue

Controls timing of glucose metabolism, insulin secretion, lipid synthesis, immune surveillance

Disruption here causes metabolic dysfunction even when sleep quantity appears normal. Shift workers exhibit this pattern

Mitochondrial ROS Modulation

Direct accumulation in mitochondria enhances electron transport efficiency and scavenges free radicals

All metabolically active cells with high mitochondrial density

Protects against oxidative damage during nocturnal repair processes

Age-related amplitude decline reduces this protective effect. Contributory factor in mitochondrial aging theories

Insulin Secretion Inhibition

MT1 activation in pancreatic beta cells suppresses cAMP-mediated insulin release during biological night

Pancreatic islet cells

Prevents nocturnal hypoglycemia but causes postprandial hyperglycemia if feeding occurs during high melatonin periods

MTNR1B polymorphism carriers show exaggerated response. Genetic basis for chronotype-metabolism interactions

Key Takeaways

Melatonin circadian clock regulation synchronizes peripheral tissue clocks through MT1 and MT2 receptor pathways in the suprachiasmatic nucleus, liver, pancreas, adipose tissue, and immune cells.

Peak melatonin secretion occurs between 2:00–4:00 AM at concentrations of 80–120 pg/mL, declining to below 10 pg/mL during daytime. This amplitude difference is the primary zeitgeber entraining 24-hour rhythms.

Blue-wavelength light exposure (460–480 nm) suppresses melatonin synthesis by 50–85% and delays circadian phase by 60–90 minutes, with metabolic effects persisting for 2–3 days.

Eating during high melatonin periods reduces insulin sensitivity by 18–23% compared to identical meals consumed earlier, mediated by MT1 receptor inhibition of beta-cell responsiveness.

Age-related melatonin amplitude decline averages 10% per decade after age 30, correlating with sleep fragmentation, advanced sleep phase, and increased metabolic syndrome prevalence.

Shift work and chronic circadian misalignment reduce melatonin amplitude by 40–60%, causing measurable degradation in glucose tolerance, leptin signaling, and mitochondrial ROS protection within seven nights.

What If: Melatonin Circadian Clock Regulation Scenarios

What If I Travel Across Multiple Time Zones — How Do I Restore Melatonin Circadian Clock Regulation Quickly?

Expose yourself to bright light (>2,500 lux) during the biological morning of your destination time zone and take 0.5–3 mg melatonin 2 hours before your desired bedtime at the destination. Light exposure advances or delays the circadian clock depending on timing. Morning light in your destination advances the clock eastward, while evening light delays it westward. Melatonin accelerates this shift by directly phase-advancing the SCN when taken during the early biological night. A controlled trial in jet-lagged travelers found this combination reduced circadian realignment time from 7–9 days to 2–4 days compared to light exposure alone.

What If My Work Schedule Requires Night Shifts — Can Melatonin Circadian Clock Regulation Be Maintained?

Partial circadian adaptation is possible but requires strategic light-dark scheduling and timed melatonin administration. Wear blue-blocking glasses (blocking 460–480 nm wavelengths) during the commute home to prevent morning light from phase-delaying your clock further. Sleep in complete darkness and take 5–10 mg melatonin immediately before daytime sleep to consolidate rest despite conflicting light cues. However, full circadian inversion rarely occurs. Most permanent night workers remain partially entrained to the 24-hour solar cycle, experiencing chronic circadian misalignment. Research suggests fixed night schedules produce less metabolic disruption than rotating shifts, which prevent any stable entrainment pattern from developing.

What If I Have Delayed Sleep Phase Disorder — Will Melatonin Fix My Late Chronotype?

Melatonin can advance circadian phase when administered 4–6 hours before habitual sleep onset, combined with morning bright light exposure upon waking. Start with 0.5 mg melatonin at 6:00 PM if your natural sleep onset is 2:00 AM, gradually advancing administration time by 15 minutes every 3 days as your sleep onset shifts earlier. This works because you're exploiting the phase response curve. Melatonin taken during the late biological afternoon/early evening advances the clock, while morning light reinforces this shift. Clinical trials in delayed sleep phase disorder patients achieved 60–90 minute phase advances within 2–3 weeks using this protocol, but compliance with consistent timing is essential. Irregular application produces no sustained benefit.

The Biological Truth About Melatonin Circadian Clock Regulation

Here's the honest answer: taking melatonin supplements at random times doesn't 'fix' your circadian rhythm. The mechanism is phase-dependent. Melatonin advances your clock only when taken during the advancing portion of the phase response curve (typically 4–6 hours before habitual sleep onset), and delays it when taken at other times. Most over-the-counter melatonin products contain 3–10 mg doses, which is 10–30 times higher than physiological nocturnal concentrations and often produces supraphysiological plasma levels that desensitize receptors with chronic use. The evidence for melatonin as a general sleep aid is weak. A 2023 Cochrane meta-analysis found melatonin reduced sleep onset latency by just 7 minutes on average in primary insomnia, far less than the 30–60 minute improvements with properly timed cognitive behavioral therapy for insomnia (CBT-I). Where melatonin demonstrates clear efficacy is circadian phase shifting in jet lag, delayed sleep phase disorder, and shift work. Contexts where the problem is clock timing, not sleep drive. Taking 10 mg melatonin at 11:00 PM because you 'can't sleep' when your endogenous melatonin already peaked two hours earlier accomplishes little except elevating plasma concentrations beyond receptor saturation.

Melatonin circadian clock regulation is biology's answer to the solar day, and like all biological clocks, it requires consistent environmental inputs to maintain precision. The suprachiasmatic nucleus integrates light information from the retina with melatonin feedback to generate stable 24-hour rhythms, but that stability depends on regular light-dark cycles, consistent sleep-wake timing, and meal schedules aligned with circadian phase. Disrupting any of these inputs. Through irregular sleep schedules, late-night eating, or excessive artificial light exposure. Degrades circadian amplitude progressively. By the time metabolic dysfunction becomes clinically apparent, the underlying circadian desynchronization has often persisted for years.

Research peptides offer emerging tools for investigating circadian restoration beyond melatonin replacement alone. Compounds like Epithalon, which influences pineal function and endogenous melatonin synthesis, and Pinealon, a pineal gland peptide bioregulator, represent experimental approaches to supporting circadian amplitude at the tissue level rather than simply supplementing the hormone itself. The field of chronopharmacology. Timing drug administration to circadian phase for optimal efficacy and minimal side effects. Continues expanding as our understanding of melatonin circadian clock regulation deepens. The peptides available through Real Peptides support investigators exploring these temporal dimensions of metabolic and neurological function, where precise amino acid sequencing and high-purity synthesis allow reproducible experimental protocols.

If your circadian rhythm feels broken, the solution isn't more melatonin. It's consistent environmental timing. Set a fixed wake time regardless of sleep quality the night before. Get bright light exposure within 30 minutes of waking. Avoid eating within 3 hours of bedtime. Dim lights after sunset and eliminate screens 90 minutes before sleep. These interventions strengthen melatonin circadian clock regulation by reinforcing the external cues your SCN evolved to track. Supplements, whether melatonin or investigational peptides, work best as precision tools within an already-stable circadian framework, not as substitutes for behavioral alignment with the 24-hour light-dark cycle that shaped every clock gene in your genome.

Frequently Asked Questions

Melatonin binds to MT1 and MT2 receptors in the suprachiasmatic nucleus, inhibiting neuronal firing through Gi-protein coupled reduction of cAMP and phase-shifting the molecular clock by modulating CLOCK-BMAL1 heterodimer activity and PER/CRY protein stability. MT1 activation facilitates sleep onset by suppressing SCN excitability, while MT2 activation directly shifts circadian phase — advancing the clock when melatonin is present during the early biological night and delaying it during the late biological night. This receptor-mediated signaling then propagates to peripheral tissues through neural and hormonal pathways, synchronizing local clock gene expression in the liver, pancreas, adipose tissue, and immune cells to the central SCN rhythm.

Chronic nightly melatonin supplementation at supraphysiological doses (3–10 mg) may cause MT1 and MT2 receptor desensitization, reducing efficacy over 4–8 weeks of continuous use. Physiological doses (0.3–0.5 mg) matching endogenous nocturnal concentrations show less receptor downregulation in controlled studies. However, melatonin is most effective as a phase-shifting tool for circadian disorders like jet lag or delayed sleep phase syndrome rather than a chronic sleep aid — for primary insomnia without circadian misalignment, cognitive behavioral therapy for insomnia (CBT-I) demonstrates superior long-term outcomes with no tolerance development. If chronic use is necessary, consider cycling off for 3–5 days every 4–6 weeks to allow receptor sensitivity to recover.

For circadian phase advancement (shifting sleep earlier), take 0.5–3 mg melatonin 4–6 hours before your current habitual sleep onset time, combined with bright light exposure upon waking. For sleep consolidation without phase shifting, take 0.3–1 mg approximately 2 hours before desired bedtime. Doses above 3 mg produce plasma concentrations 10–30 times higher than physiological nighttime levels and offer no additional circadian benefit while increasing next-day grogginess risk. Timing is more critical than dose — melatonin taken during the wrong circadian phase can delay your clock rather than advance it, so consistency with administration time relative to your current sleep schedule is essential for achieving the intended effect.

Blue-wavelength light (460–480 nm) directly stimulates melanopsin-containing intrinsically photosensitive retinal ganglion cells, which signal the suprachiasmatic nucleus to suppress melatonin synthesis in the pineal gland by 50–85% depending on intensity and duration. Two hours of evening tablet or smartphone use delays melatonin onset by 60–90 minutes on average, effectively phase-delaying your circadian clock. This suppression persists even after the light source is removed — studies show circadian phase delays and reduced melatonin amplitude lasting 2–3 days after a single night of bright blue light exposure before bed. Wearing blue-blocking glasses (blocking wavelengths below 525 nm) after sunset prevents this suppression while allowing other wavelengths for normal vision.

Melatonin circadian clock regulation suppresses insulin secretion from pancreatic beta cells by 40–60% during nocturnal hours when melatonin concentrations peak, creating adaptive circadian insulin resistance that prevents hypoglycemia during overnight fasting. When food is consumed during this high-melatonin period, glucose disposal is impaired because insulin response is blunted by MT1 receptor activation in beta cells. A controlled trial found identical 500-calorie meals consumed at 10:00 PM versus 6:00 PM produced 23% higher postprandial glucose and 18% lower insulin sensitivity. This effect is exaggerated in carriers of the MTNR1B G-allele polymorphism, who show 2–3 times higher type 2 diabetes risk with habitual late eating due to stronger melatonin-mediated insulin suppression.

Melatonin works by phase-shifting and synchronizing the circadian clock through MT1 and MT2 receptor activation in the suprachiasmatic nucleus, addressing the timing of sleep rather than inducing sedation directly. Benzodiazepines and Z-drugs (zolpidem, eszopiclone) act on GABA-A receptors to enhance inhibitory neurotransmission, producing sedation and amnesia but without correcting underlying circadian misalignment. While sleep medications reduce sleep onset latency by 15–30 minutes, they suppress slow-wave sleep architecture and carry tolerance, dependence, and next-day cognitive impairment risks. Melatonin is most effective when the sleep problem is circadian in origin — wrong timing rather than inability to initiate or maintain sleep — making it superior for jet lag, shift work, and delayed sleep phase disorder but less effective than CBT-I for primary insomnia without circadian disruption.

Peak nocturnal melatonin concentrations decline by approximately 10% per decade after age 30, dropping from 100–120 pg/mL in young adults to 40–50 pg/mL by age 70. This age-related amplitude reduction correlates with sleep fragmentation, advanced sleep phase (earlier bedtimes and wake times), and increased metabolic syndrome prevalence. Timed-release melatonin formulations (2–5 mg administered 2 hours before bedtime) have demonstrated improvements in sleep consolidation and glucose homeostasis in older adults in controlled trials, suggesting partial restoration of circadian amplitude. However, supplementation cannot fully replicate the endogenous secretion pattern and does not address potential age-related changes in receptor sensitivity or downstream clock gene expression in peripheral tissues.

Shift work, particularly rotating schedules, prevents stable entrainment of the circadian clock to any consistent light-dark cycle, causing chronic circadian misalignment even when total sleep time appears adequate. Melatonin secretion patterns in shift workers show flattened amplitude, irregular timing, and reduced peak concentrations — studies document 40–60% amplitude reduction within seven consecutive night shifts. While strategic light-dark management (bright light during night work, darkness during daytime sleep, blue-blocking glasses during morning commutes) and timed melatonin administration can improve daytime sleep consolidation, most permanent night workers remain partially entrained to the solar cycle rather than fully inverting their circadian phase. Fixed night schedules produce less metabolic disruption than rotating shifts because they allow partial adaptation, but neither approach fully preserves normal melatonin circadian clock regulation.

Melatonin metabolism occurs primarily through CYP1A2 hepatic enzymes, so fluvoxamine (SSRI), ciprofloxacin (antibiotic), and other CYP1A2 inhibitors can increase melatonin plasma concentrations by 5–12 times, potentially causing excessive daytime sedation. Conversely, CYP1A2 inducers like cigarette smoking reduce melatonin concentrations by accelerating clearance. Caffeine antagonizes adenosine receptors and delays melatonin onset when consumed within 6 hours of bedtime. Beta-blockers used for hypertension suppress nocturnal melatonin synthesis by blocking beta-adrenergic signaling in pinealocytes, contributing to insomnia as a side effect. Combining melatonin with other circadian-active compounds — bright light therapy, caffeine restriction, or investigational peptides affecting pineal function — requires careful timing to avoid conflicting phase-shifting signals that could worsen rather than improve circadian alignment.

Melatonin regulates circadian immune surveillance patterns, with natural killer cell activity, T-cell proliferation, and antibody production peaking during nocturnal hours when melatonin concentrations are highest. MT1 and MT2 receptors expressed on lymphocytes and macrophages modulate cytokine secretion timing — melatonin suppresses pro-inflammatory cytokines (TNF-alpha, IL-6) during the biological night while facilitating tissue repair processes. Chronic circadian misalignment from shift work or social jetlag disrupts this pattern, causing elevated baseline inflammation (measured by C-reactive protein and IL-6) and reduced vaccine response efficacy. A study in rotating shift workers found 34% lower antibody titers following influenza vaccination compared to day workers, an effect attributed to mistimed immune activation during periods when melatonin-regulated immune enhancement should occur. Restoring melatonin circadian clock regulation through behavioral interventions or timed supplementation may support normal immune rhythms, though direct clinical evidence remains limited.